Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | PDE1A | P54750 | 1/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7621510 | 0.81 | ADORA1 (0.62) | ADORA1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL6363706 | 0.79 | ADORA1 (0.48) | ADORA1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL7624397 | 0.78 | ADORA1 (0.49) | ADORA1MEN1KMT2APDE5AALDH1A1 | |
| SCHEMBL5646 | 0.77 | PDE2A (0.61) | ADORA1MEN1KMT2APDE5AKDM4E | |
| SCHEMBL10309248 | 0.76 | MEN1 (0.65) | ADORA1MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL19583186 | 0.76 | KDM4E (0.43) | ADORA1MEN1KMT2APDE5AKDM4E | |
| SCHEMBL4796596 | 0.75 | PDE1A (0.46) | ADORA1MEN1KMT2APDE5AKDM4E | |
| SCHEMBL6234430 | 0.74 | PDE5A (0.64) | MEN1KMT2APDE5AKDM4EALDH1A1 | |
| SCHEMBL272517 | 0.74 | KDM4E (0.41) | ADORA1MEN1KMT2APDE5AKDM4E | |
| SCHEMBL2053839 | 0.73 | PDE5A (0.42) | ADORA1MEN1KMT2APDE5AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3900712-A1 | GPCR HETEROMER INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2021-10-27 | — | — | EP | claimed |
| EP-3727371-A1 | GPCR HETEROMER INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2020-10-28 | — | — | EP | claimed |
| CN-111741752-A | GPCR heteromer inhibitors and uses thereof | GPCR治疗公司 | 2020-10-02 | — | — | CN | claimed |
| US-9555037-B2 | Method of using vasoconstrictive agents during energy-based tissue therapy | COVIDIEN AG | 2017-01-31 | — | — | US | claimed |
| US-20160151374-A1 | METHOD OF USING VASOCONSTRICTIVE AGENTS DURING ENERGY-BASED TISSUE THERAPY | SHERWOOD SERVICES AG (CH) | 2016-06-02 | — | — | US | claimed |
| US-9271985-B2 | Method of using vasoconstrictive agents during energy-based tissue therapy | COVIDIEN AG (CH) | 2016-03-01 | — | — | US | claimed |
| US-20150164903-A1 | METHOD OF USING VASOCONSTRICTIVE AGENTS DURING ENERGY-BASED TISSUE THERAPY | SHERWOOD SERVICES AG (CH) | 2015-06-18 | — | — | US | claimed |
| US-7767686-B2 | Method of using adenosine receptor blockers during tissue ablation | COVIDIEN AG (CH) | 2010-08-03 | — | — | US | claimed |
| US-20080275068-A1 | administering a vasoconstrictive agent such as an adenosine receptor antagonist ( 1,3-dipropyl-8-cyclopentylxanthine, 8-(3-Chlorostyryl)caffeine, 6-carboxy-methyl-5,9-dihydro-9-methyl-2-phenyl-[1,2,4]-triazolo[5,1-a][2,7]naphthyridine) to the mammal to increases the size of the coagulation zone | COVIDIEN AG (CH) | 2008-11-06 | — | — | US | claimed |
| US-20070207979-A1 | Method of using adenosine receptor blockers during tissue ablation | SHERWOOD SERVICES AG | 2007-09-06 | — | — | US | claimed |
| US-20070208042-A1 | Method of using vasoconstrictive agents during energy-based tissue therapy | SHERWOOD SERVICES AG | 2007-09-06 | — | — | US | claimed |
| US-12585199-B2 | Overlay correction method, and exposure method and semiconductor device manufacturing method including overlay correction method | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2026-03-24 | — | — | US | disclosed |
| US-20250387363-A1 | LIQUID EPINEPHRINE PRODRUG FORMULATIONS AND LIQUID EPINEPHRINE FORMULATIONS | INSIGNIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250316979-A1 | POE PD Redundant System | MICROCHIP TECHNOLOGY INCORPORATED (US) | 2025-10-09 | — | — | US | disclosed |
| US-12321091-B2 | Device and method for determining placements of pattern elements of a reflective photolithographic mask in the operating environment thereof | CARL ZEISS SMT GMBH (DE) | 2025-06-03 | — | — | US | disclosed |
| US-7767686-B2 | Method of using adenosine receptor blockers during tissue ablation | COVIDIEN AG (CH) | 2010-08-03 | — | — | US | disclosed |
| US-20090136460-A1 | USE OF ADENOSINE RECEPTOR LIGANDS TO PROMOTE CELL ADHESION IN CELL-BASED THERAPIES | VANDERBILT UNIVERSITY | 2009-05-28 | — | — | US | disclosed |
| US-20080275068-A1 | administering a vasoconstrictive agent such as an adenosine receptor antagonist ( 1,3-dipropyl-8-cyclopentylxanthine, 8-(3-Chlorostyryl)caffeine, 6-carboxy-methyl-5,9-dihydro-9-methyl-2-phenyl-[1,2,4]-triazolo[5,1-a][2,7]naphthyridine) to the mammal to increases the size of the coagulation zone | COVIDIEN AG (CH) | 2008-11-06 | — | — | US | disclosed |
| US-20070207979-A1 | Method of using adenosine receptor blockers during tissue ablation | SHERWOOD SERVICES AG | 2007-09-06 | — | — | US | disclosed |
| US-20070208042-A1 | Method of using vasoconstrictive agents during energy-based tissue therapy | SHERWOOD SERVICES AG | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207979-A1 | Method of using adenosine receptor blockers during tissue ablation | ADORA2A, ADORA2B, ADORA3 | ADORA1 4/4885MEN1 2573/4885KMT2A 3150/4885 |
| US-20070208042-A1 | Method of using vasoconstrictive agents during energy-based tissue therapy | PLAT, TEK, PLG | ADORA1 503/4885MEN1 2440/4885KMT2A 3816/4885 |
| US-12585199-B2 | Overlay correction method, and exposure method and semiconductor device manufacturing method including overlay correction method | RHOA, SRMS, SORBS1 | ADORA1 3985/4885MEN1 3344/4885KMT2A 627/4885 |
| US-20150164903-A1 | METHOD OF USING VASOCONSTRICTIVE AGENTS DURING ENERGY-BASED TISSUE THERAPY | PLAT, TEK, PLG | ADORA1 503/4885MEN1 2440/4885KMT2A 3816/4885 |
| US-20160151374-A1 | METHOD OF USING VASOCONSTRICTIVE AGENTS DURING ENERGY-BASED TISSUE THERAPY | PLAT, TEK, PLG | ADORA1 503/4885MEN1 2440/4885KMT2A 3816/4885 |
| US-20080275068-A1 | administering a vasoconstrictive agent such as an adenosine receptor antagonist ( 1,3-dipropyl-8-cyclopentylxanthine, 8-(3-Chlorostyryl)caffeine, 6-carboxy-methyl-5,9-dihydro-9-methyl-2-phenyl-[1,2,4]-triazolo[5,1-a][2,7]naphthyridine) to the mammal to increases the size of the coagulation zone | ADORA2A, ADORA1, ADORA3 | ADORA1 2/4885MEN1 2712/4885KMT2A 2041/4885 |
| US-20250387363-A1 | LIQUID EPINEPHRINE PRODRUG FORMULATIONS AND LIQUID EPINEPHRINE FORMULATIONS | ADRB3, ADRB2, ADRB1 | ADORA1 126/4885MEN1 1013/4885KMT2A 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.